The Surprising Reason Regeneron Pharmaceuticals Just Dropped 10%
Quick Take
Regeneron Pharmaceuticals' stock fell 10% due to unexpected clinical trial results.
Key Points
- Clinical trial outcomes disappointed investors.
- Regeneron's drug efficacy was questioned.
- Market reaction reflects investor sentiment.
📖 Reader Mode
~1 min read
Regeneron Pharmaceuticals (REGN) stock crashed Monday after its experimental melanoma treatment failed in Phase 3 testing, leading at least 10 analysts to cut their price targets. The company aimed to show improvement in progression-free survival, or PFS, in patients with never-before-treated metastatic melanoma. Fianlimab recipients had a 5.1-month improvement in PFS — how long they lived before their cancer progressed.…
Copyright ©2026 Investor's Business Daily, LLC. All rights reserved. 87990cbe856818d5eddac44c7b1cdeb8
— Originally published at investors.com
More from Yahoo Finance
See more →
4h ago
FeaturedOriginal
These Super Stocks Could Be the Biggest Winners in the AI Inference and Agentic AI Economy
AI Summary
The article highlights top stocks poised for growth in the AI inference and agentic AI sectors.
